Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avir Green Hills Biotechnology has initiated a clinical Phase I study with its intranasal vaccine deltaFLU against pandemic influenza.
Subscribe to our email newsletter
The randomized, double-blind phase I study of the pandemic vaccine deltaFLU will be run at the Department of Clinical Pharmacology, Medical University of Vienna. The aim of Phase I study is to analyze the safety and efficacy of the vaccine in healthy volunteers.
According to the company, this novel generation of a live-attenuated vaccine based on the deletion of the NS1 gene has shown superior preclinical data.
Thomas Muster, founder and CEO of Avir Green Hills, said: “Our vaccine lacks the pathogenicity factor NS1. Due to this deletion, the vaccine is likely to show a superior safety profile. We are confident that the pandemic deltaFLU vaccine will be tolerated even at high doses.”